Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00630825 · ClinicalTrials.gov registry record · Phase 2
A Study of Dose Titration of LY2189265 in Overweight Participants With Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 262
- Enrollment target
NCT00630825: Completed Phase 2 study, sponsored by Eli Lilly and Company.
NCT00630825 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 262 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00630825, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 262 participants
- Enrollment target
Study Summary
To study once weekly injections of LY2189265 compared to placebo on blood glucose by measuring glycosylated hemoglobin (HbA1c) change from baseline after 16 weeks in overweight Type 2 Diabetes Mellitus participants.
Primary Outcome
Once weekly injections of LY2189265 (titrated and non-titrated doses) compared to placebo on blood glucose were evaluated. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusting for treatment, combination of oral medications, and baseline glycosylated hemoglobin (HbA1c).
Interventions
- DRUG Placebo
- DRUG LY2189265
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 262 participants |
| Start Date | 2008-04 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
What the finished NCT00630825 record still lists
NCT00630825 is an interventional study that assigns participants to a tested intervention. The registered 262 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00630825 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00630825 about?
NCT00630825 is a clinical study titled "A Study of Dose Titration of LY2189265 in Overweight Participants With Type 2 Diabetes Mellitus". To study once weekly injections of LY2189265 compared to placebo on blood glucose by measuring glycosylated hemoglobin (HbA1c) change from baseline after 16 weeks in overweight Type 2 Diabetes Mellitus participants.
What is the current status of trial NCT00630825?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 262 participants. The study started on 2008-04. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00630825?
The interventions under investigation include: Placebo (DRUG), LY2189265 (DRUG).
Who is sponsoring clinical trial NCT00630825?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00630825's enrollment target sits among peer trials
262 210th of 2000 higher than 1,791 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03713268 · 262 participants
Intraoperative OCT Guidance of Intraocular Surgery II
- NCT06074380 · 262 participants · Phase 4
Non Inferiority Trial Investigating Surfactants Administered Via MIST
- NCT06293703 · 262 participants · NA
Effect of Limb Length Ratio on Roux-en-Y Gastric Bypass Outcomes (CLIMB II Study)
- NCT06780137 · 262 participants · Phase 1
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia